Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Platinum-Resistant Fallopian Tube Carcinoma”

99 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 99 results

Testing effectiveness (Phase 2)Study completedNCT03776812
What this trial is testing

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Recurrent Ovarian CancerRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma
Corcept Therapeutics 178
Large-scale testing (Phase 3)Active Not RecruitingNCT02839707
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube High Grade Serous AdenocarcinomaOvarian High Grade Serous AdenocarcinomaOvarian Seromucinous Carcinoma+16 more
National Cancer Institute (NCI) 444
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Not applicableEnded earlyNCT03412630
What this trial is testing

Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
ECOG-ACRIN Cancer Research Group 1
Testing effectiveness (Phase 2)Looking for participantsNCT04055649
What this trial is testing

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Who this might be right for
Malignant Ovarian Epithelial TumorPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian Carcinoma+7 more
Ira Winer 62
Testing effectiveness (Phase 2)Ended earlyNCT04019288
What this trial is testing

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
M.D. Anderson Cancer Center 12
Early research (Phase 1)Study completedNCT02898207
What this trial is testing

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Who this might be right for
Metastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Primary Peritoneal Serous Adenocarcinoma+16 more
National Cancer Institute (NCI) 28
Large-scale testing (Phase 3)Looking for participantsNCT05281471
What this trial is testing

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Who this might be right for
Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerFallopian Tube Cancer+4 more
Genelux Corporation 186
Early research (Phase 1)Active Not RecruitingNCT05617755
What this trial is testing

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Who this might be right for
Carcinoma, Ovarian EpithelialOvarian NeoplasmsFallopian Tube Neoplasms+6 more
Arsenal Biosciences, Inc. 19
Testing effectiveness (Phase 2)WithdrawnNCT05672095
What this trial is testing

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+3 more
City of Hope Medical Center
Testing effectiveness (Phase 2)UnknownNCT04376073
What this trial is testing

Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
Jihong Liu 40
Testing effectiveness (Phase 2)Looking for participantsNCT05231122
What this trial is testing

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more
Roswell Park Cancer Institute 80
Large-scale testing (Phase 3)Study completedNCT00382811
What this trial is testing

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

Who this might be right for
Fallopian Tube CancerPeritoneal NeoplasmsOvarian Cancer
MEI Pharma, Inc. 142
Testing effectiveness (Phase 2)Study completedNCT01652079
What this trial is testing

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Massachusetts General Hospital 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT02595892
What this trial is testing

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Ovarian Serous TumorRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+1 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Study completedNCT00510653
What this trial is testing

Gleevec Study for Patients With Ovarian Cancer

Who this might be right for
Ovarian Cancer
M.D. Anderson Cancer Center 73
Testing effectiveness (Phase 2)UnknownNCT02188550
What this trial is testing

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

Who this might be right for
Ovarian CancerEndometrial Cancer
Sinai Hospital of Baltimore 20
Early research (Phase 1)Active Not RecruitingNCT03586661
What this trial is testing

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial Adenocarcinoma+8 more
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Study completedNCT00617773
What this trial is testing

Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Recepta Biopharma 31
Early research (Phase 1)Looking for participantsNCT06483048
What this trial is testing

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+13 more
Mayo Clinic 12
Load More Results